A phase III, double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy and safety of Ravulizumab

A phase III, double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy and safety of Ravulizumab administered intravenously in adult participants at high risk of delayed graft function after kidney transplantation.

Open

Protocol code: ALXN1210-DGF-321
EudraCT code: _
Research group: Nephrology and kidney transplantation
Service: Nephrology
Principal investigator: Moreso Mateos, Francesc
Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
Phase: Fase III